Hong‐Chiang Chang

About

Hong-Chiang Chang is a leading urological researcher whose work focuses on improving diagnostic and surgical outcomes for prostate and renal cancers. His primary research areas include prostate cancer biomarker prediction and nephrometry scoring for partial nephrectomy. Dr. Chang’s major contribution lies in evaluating the clinical utility of the Prostate Health Index (PHI) and its derivative, %p2PSA, demonstrating their predictive accuracy for aggressive pathological outcomes in prostate cancer patients undergoing radical prostatectomy. His 2020 study on this topic has garnered 9 citations, highlighting its impact on refining preoperative risk stratification. Additionally, he has advanced the field of nephron-sparing surgery by comparing the Diameter-Axial-Polar (DAP) and RENAL nephrometry scores to predict long-term trifecta outcomes—encompassing surgical, oncological, and functional success—in robot-assisted partial nephrectomy for renal cell carcinoma. This work, cited 2 times, provides valuable guidance for surgical planning. Through these contributions, Dr. Chang is helping clinicians make more informed decisions, ultimately improving patient care in urologic oncology.

Research Focus

Key Achievements

Top Papers

1. 1
   Preoperative %p2PSA and Prostate Health Index Predict Pathological Outcomes in Patients with Prostate Cancer Undergoing Radical Prostatectomy

   9 citations · 2020
2. 2
   Comparing the Predictive Values of Diameter-Axial-Polar and Renal Scores for Long-Term Trifecta Outcomes in Robot-Assisted Partial Nephrectomy for Renal Cell Carcinoma

   2 citations · 2020

Key Collaborators

Contact & Links